Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $63.0 million.

  • Foghorn Therapeutics' Shares Outstanding (Weighted Average) rose 68.12% to $63.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 68.12%. This contributed to the annual value of $54.9 million for FY2024, which is 3079.24% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Shares Outstanding (Weighted Average) is $63.0 million, which was up 68.12% from $63.0 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) peaked at $63.0 million during Q3 2025, and registered a low of $36.8 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $41.8 million (2023), whereas its average is $46.4 million.
  • In the last 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) surged by 61431.2% in 2021 and then soared by 68.12% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $37.2 million in 2021, then rose by 11.89% to $41.6 million in 2022, then rose by 0.92% to $42.0 million in 2023, then surged by 30.79% to $54.9 million in 2024, then grew by 14.81% to $63.0 million in 2025.
  • Its last three reported values are $63.0 million in Q3 2025, $63.0 million for Q2 2025, and $62.8 million during Q1 2025.